-
Mashup Score: 0Dr Saad on the FDA Approval of Darolutamide in mCSPC - 18 minute(s) ago
Fred Saad, MD, discusses the FDA’s approval of darolutamide without chemotherapy for metastatic castration-sensitive prostate cancer
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Inavolisib Plus Palbociclib/Fulvestrant Earns Positive CHMP Opinion for PIK3CA-Mutated, ER+/HER2– Advanced Breast Cancer - 1 hour(s) ago
The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
The EMA’s CHMP recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER+ advanced breast cancer. #bcsm #oncology https://t.co/ioxwg9aGBP
-
-
Mashup Score: 0Dr O’Meara on the Evolving Role of ADCs in HER2+ Breast Cancer - 2 hour(s) ago
Tess O’Meara, MD, highlights the role of antibody-drug conjugates for the treatment of patients with HER2-positive breast cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
WATCH 📺: @tess_omeara of @DanaFarberNews highlights the role of antibody-drug conjugates for the treatment of patients with HER2-positive breast cancer. @ASCO #ASCO25 #bcsm https://t.co/RBcTjH0nNi
-
-
Mashup Score: 3
RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.
Source: www.onclive.comCategories: General Medicine NewsTweet-
RET Inhibitor Rechallenge Demonstrates Activity in Previously Treated #NSCLC @ASCO #ASCO25 https://t.co/tgpkfI0t89
-
-
Mashup Score: 4
IMforte data highlight potential for lurbinectedin plus atezolizumab to become a new SOC for first-line maintenance treatment in ES-SCLC.
Source: www.onclive.comCategories: General Medicine NewsTweet-
First-Line Maintenance Lurbinectedin Plus Atezolizumab Boosts Survival in ES-SCLC @LuisPaz_Ares @H12Octubre @ASCO #ASCO25 #lcsm #Oncology https://t.co/5EdXt3UGNR
-
-
Mashup Score: 0Dr Goldman on the Efficacy of Telisotuzumab Vedotin in Advanced NSCLC With c-MET Overexpression - 5 hour(s) ago
Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin for the treatment of locally advanced or metastatic NSCLC with c-MET overexpression.
Source: www.onclive.comCategories: General Medicine NewsTweet-
WATCH 📺: Jonathan W. Goldman, MD, of @UCLAHealthJCCC, discusses the role of telisotuzumab vedotin for the treatment of locally advanced or metastatic NSCLC with c-MET overexpression. @ASCO #ASCO25 #lcsm #oncology https://t.co/9Dr6taLVSR
-
-
Mashup Score: 2
The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Acoustic Cluster Therapy Platform Boosts Tumor Shrinkage in Metastatic #CRC https://t.co/ZLWvh1sLwt
-
-
Mashup Score: 1GLP-1 Agonists Are Linked to Modest Decrease in Obesity-Related Cancers in Adults With Diabetes - 7 hour(s) ago
The use of GLP-1 agonists was not associated with higher cancer rates and led to a decrease in obesity-related cancers in adults with diabetes.
Source: www.onclive.comCategories: General Medicine NewsTweet-
GLP-1 Agonists Are Linked to Modest Decrease in Obesity-Related Cancers in Adults With Diabetes @nyugrossman @ASCO #ASCO25 #oncology https://t.co/Z1GM3NoQoo
-
-
Mashup Score: 2Dr Sammons on the Efficacy of RLY-2608 Plus Fulvestrant in PIK3CA-Mutant HR+/HER2– Breast Cancer - 8 hour(s) ago
Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
WATCH 📺: @drsarahsam of @DanaFarber discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer. @ASCO #ASCO25 #bcsm https://t.co/JD2RuT1YPY
-
-
Mashup Score: 5Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer - 9 hour(s) ago
Combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways are under investigation to improve outcomes in patients with endometrial cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Investigations are underway to evluate combinations targeting PI3K/AKT/mTOR and MAPK/ERK pathways to improve outcomes in patients with #EndometrialCancer. @PamSolimanMD @MDAndersonNews Read more here: https://t.co/fSpsRE9Aa7 https://t.co/ZW0lnHUj3V
-
ICYMI📺: Fred Saad, MD, of @cancermtl, discusses the FDA’s approval of darolutamide without chemotherapy for metastatic castration-sensitive prostate cancer. #pcsm #oncology https://t.co/ofYCuWG9RJ